Muutke küpsiste eelistusi

E-raamat: Contemporary Targeted Therapies in Rheumatology

Edited by (National Institute of Arthritis, Bethesda, USA), Edited by (University of Vienna, Austria)
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 18-Oct-2007
  • Kirjastus: CRC Press
  • Keel: eng
  • ISBN-13: 9781135174637
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 305,50 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Raamatukogudele
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 18-Oct-2007
  • Kirjastus: CRC Press
  • Keel: eng
  • ISBN-13: 9781135174637
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the pathogenesis of rheumatic diseases.Along with the clinical success of some of these targeted approaches, new information has been generated from their application concerning the pathophysiologic mechanisms underlying rheumatic diseases and, as a result, new targets have been identified.The ongoing dialogue between basic scientists, clinical investigators, metrologists and clinicians remains an essential component for the further development, refinement, integration and optimization of targeted therapies of the rheumatic diseases. The goal of this volume is to provide comprehensive, up to date information on all aspects of the rapidly evolving development of targeted therapies of the rheumatic diseases to foster further advances to improve therapy of patients with these conditions.

Targeted Therapies in Rheumatology established itself as an excellent reference for all those needing to know about the clinical implications of new drugs and developments for patients suffering from rheumatoid arthritis. This volume takes up the further developments that have occurred in several of the drug therapies covered in the first volume, as well as looking at the latest areas of promising research.

Arvustused

Review for the previous volume from Annals of Internal Medicine (140:2, 2004):

"This is a quality textbook that highlights the important advances that have enhanced, or are likely to enhance, the treatment of many serious chronic inflammatory and autoimmune diseases. Each of the authors was selected on the basis of their published contributions to an exciting literature"

List of Contributors
ix
Section I - Cells and cell surface receptors
T cells - overview - update
1(6)
Hendrik Schulze-Koops
Joachim R Kalden
Pathways of T-cell costimulation
7(16)
Brendan J Classon
Steven G Nadler
Suzanne J Suchard
Regulatory T cells
23(8)
Harald von Boehmer
B-cell antigen receptor signaling and autoimmunity
31(14)
Esra Nutku-Bilir
Aimee E Pugh-Bernard
Stephen Gauld
Kevin Merrell
John C Cambier
Macrophages in rheumatoid arthritis
45(18)
Peter LEM van Lent
Wim B van den Berg
Dendritic cells
63(16)
Viviana Lutzky
Ranjeny Thomas
Osteoclasts
79(6)
Georg Schett
Kurt Redlich
Cell contact dependence of inflammatory events
85(20)
Danielle Burger
Jean-Michel Dayer
Nicolas Molnarfi
Toll-like receptors: possible targets for novel treatments for rheumatoid arthritis
105(16)
Constantinos Brikos
Luke AJ O'Neill
Cadherin-11 mediates synovial lining organization: a new therapeutic target in inflammatory arthritis
121(12)
Erika H Noss
Michael B Brenner
Section II - Cytokines, chemokines and other effector molecules
TNF-α
133(16)
Marc Feldmann
Ravinder N Maini
Update on interleukin-6
149(10)
Norihiro Nishimoto
Tadamitsu Kishimoto
Interleukin-13
159(16)
Marion T Kasaian
Mary Collins
Biology of interleukin-15
175(10)
Iain B Mclnnes
Too Y Liew
J Alastair Grade
Interleukin-17: a new target in arthritis
185(10)
Pierre Miossec
Myew-Ling Toh
Saloua Zrioual
The role of interleukin-18 in inflammation
195(16)
Charles A Dinarello
Interleukin-21
211(14)
Rosanne Spolski
Warren J Leonard
The biology of human interleukin-32
225(6)
Charles A Dinarello
Soo-Hyun Kim
The interferons
231(20)
Lars Edvard Ronnblom
Maija-Leena Eloranta
Gunnar Aim
Osteoprotegerin
251(14)
Allison R Pettit
Ellen M Gravallese
Update: inflammatory, angiogenic, and homeostatic chemokines and their receptors
265(20)
Zoltan Szekanecz
Alisa Erika Koch
Section III - Transcription factors and signaling molecules
New developments in NF-κB
285(12)
Keith Brown
Estefania Claudio
Ulrich K Siebenlist
Roles of the JAK-STAT signaling pathways in rheumatoid arthritis
297(8)
Bradley J Bloom
Sam Zwillich
Anthony Milici
Paul Changelian
Suppressor of cytokine signaling (SOCS) proteins as therapeutic targets in rheumatoid arthritis
305(22)
Paul John Egan
Peter K Wong
Ian P Wicks
Wnt signaling for targeted therapies in rheumatology
327(2)
Kathleen T Rousche
Dolores Baksh
Rocky S Tuan
Section IV - Inflammatory mediators and matrix molecules
Inflammatory mediators: update on cyclooxygenases and prostaglandin synthases
329(10)
Leslie J Crofford
Mohit Kapoor
Fumiaki Kojima
Complement and pregnancy loss
339(14)
Jane E Salmon
V Michael Holers
Matrix metalloproteinases
353(14)
Thomas Pap
Steffen Gay
Georg Schett
MMPs and ADAMs as targets for therapies in arthritis
367(18)
Hideaki Nagase
Gillian Murphy
Andrew Parker
Section V - Targeted therapies in human and experimental rheumatic diseases
Update on proinflarnmatory cytokine blockade in rheumatoid arthritis
385(7)
Ferdinand C Breedveld
Targeting interleukin-1 in rheumatic diseases
392(9)
Cem Gabay
William P Arend
Update on targeted therapy in psoriatic arthritis
401(12)
Philip J Mease
Spondyloarthritides
413(6)
Joachim Sieper
Jurgen Braun
Early arthritis
419(6)
Paul Emery
Sally Cox
Juvenile arthritis
425(10)
Patricia Woo
Update - systemic lupus erythematosus
435(14)
Bevra Hannahs Hahn
Sonwoo Lee
Vasculitis
449(18)
Gary S Hoffman
Leonard H Calabrese
Carol A Langford
Myositis
467(18)
Frederick W Miller
TNF blockade in orphan rheumatic diseases
485(12)
Michael Voulgarelis
Haralampos M Moutsopoulos
Overview of the safety of TNF inhibitors
497(12)
Arthur Kavanaugh
John J Cush
Anti-CD20 to further targeted therapies in rheumatology
509(18)
Kristine P Ng
David Alsenberg
Targeting B-lymphocyte stimulator (BLyS) in immune-based rheumatic diseases: a therapeutic promise waiting to be fulfilled
527(16)
William Stohl
Anti-CD3 antibody - a history of successful immune interventions
543(10)
Damien Bresson
Matthias von Herrath
Alefacept
553(8)
Thomas A Luger
Clinical targeting of interleukin-15
561(8)
Iain B Mclnnes
Foo Y Liew
Clinical prospects of MAPK inhibitors
569(12)
Susan E Sweeney
Gary S Firestein
Clinical prospects of NF-κB inhibitors to further targeted therapies in rheumatology
581(20)
Stefan K Drexler
Jeremy JO Turner
Brian M Foxwell
Outcomes assessment in rheumatic disease
601(16)
Daniel Aletaha
Josef SSmolen
Index 617


Josef S. Smolen, Peter E. Lipsky